Viramune is a medicine containing the active ingredient(s) nevirapine. On this page you will find out more about Viramune, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: nevirapine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Viramune 200 mg uncoated tablet, 60
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Viramune (nevirapine) immediate-release tablets and oral suspension in combination with antiretroviral agents is indicated for the treatment of HIV-1 infection in adults and children over the age of 2 months. Viramune XR (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of HIV-1 infection in adults and children over the age of three years. Extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. Resistant virus emerges rapidly when Viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. Therefore, Viramune should always be administered in combination with at least two additional antiretroviral agents.
Table of characteristics
|Visual appearance||white, oval, biconvex, uncoated tablets (9.3 x 19. 1mm). One side is embossed with '54 193' with a single bisect line separating the '54' and '193'. The other side has a single bisect line.|
|Dosage Form||Tablet, uncoated|
|Route of administration||Oral|
100 tablets: Prescription Only Medicine, or Prescription Animal Remedy
14 tablets: Prescription Only Medicine, or Prescription Animal Remedy
60 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||36 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.